8 completed, 4 terminated, 2 active not recruiting, 1 recruiting. 16 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 8, Terminated 4, Active not recruiting 2, Recruiting 1, Unknown 1 |
| Phase 1 | 9 | Completed 5, Terminated 2, Active not recruiting 1, Unknown 1 |
Follow Array BioPharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma Binimetinib, Imatinib - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | University of California, San Francisco | 25 | 2021-03-03 | 2026-08-18 |
| Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma Binimetinib, Nivolumab, Questionnaire Administration - Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8 | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 3 | 2020-12-03 | 2024-12-04 |
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab - Renal Cell Carcinoma, Melanoma | Phase 1 / Phase 2 | Active not recruiting | Dan Zandberg | 70 | 2020-06-11 | 2025-11-06 |
| Lorlatinib Combinations in Lung Cancer Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation | Phase 1 / Phase 2 | Unknown | Massachusetts General Hospital | 96 | 2020-05-01 | 2021-03-10 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers Binimetinib, Encorafenib - Advanced BRAF Mutant Cancers | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2019-02-14 | 2024-10-21 |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Binimetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 2 | Completed | University of Alabama at Birmingham | 45 | 2017-11-28 | 2025-05-02 |
| BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) Encorafenib, Binimetinib - Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation | Phase 2 | Completed | University of Heidelberg Medical Center | 12 | 2016-06-01 | 2023-11-24 |
| Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients Filanesib, pomalidomide and dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | PETHEMA Foundation | 47 | 2015-09-01 | 2022-07-27 |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations WNT974, LGX818, Cetuximab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2014-12-01 | 2017-10-09 |
| MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy MEK 162 - Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2014-08-27 | 2021-04-20 |
| LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma LGX818 - Melanoma | Phase 2 | Terminated | Array BioPharma | 15 | 2013-11-01 | 2017-01-09 |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation LGX818 - Melanoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 7 | 2013-07-01 | 2024-07-16 |
| Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. LEE011, LGX818 - Locally Advanced Metastatic BRAF Mutant Melanoma | Phase 1 / Phase 2 | Terminated | Array BioPharma | 28 | 2013-07-01 | 2016-09-13 |
| First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma Gemcitabine, Cisplatin, MEK162 - Advanced Biliary Tract Carcinoma | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 42 | 2013-04-01 | 2020-11-17 |
| A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral, Gemcitabine, nucleoside analogue; intravenous - Advanced Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2009-03-01 | 2012-10-04 |
Melanoma (6) · Recurrence (3) · Multiple Myeloma (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Neurofibroma (1) · Neurofibroma, Plexiform (1) · Neurofibromatoses (1)
binimetinib (8) · encorafenib (6) · Gemcitabine (2) · Nivolumab (2) · ARRY-334543 (1) · Cetuximab (1) · Cisplatin (1) · Crizotinib (1) · Dexamethasone (1) · Imatinib Mesylate (1) · LGK974 (1) · Nucleosides (1) · avelumab (1) · filanesib (1) · liposomal doxorubicin (1)
United States (14) · Australia (3) · Canada (3) · Spain (3) · Germany (2) · Netherlands (2) · Belgium (1) · France (1) · Israel (1) · Italy (1) · Singapore (1) · Switzerland (1)
Bruce Korf, MD, PhD (1) · Dan Zandberg, MD (1) · Farhad Ravandi-Kashani, MD (1) · Ghassan Abou-Alfa, MD (1) · Ibiayi Dagogo-Jack, MD (1) · Katy Tsai, MD (1) · Laura Huppert, MD (1) · Marc S. Raab, PD Dr. med. (1) · Ocio Enrique, DR (1) · Paul Chapman, MD (1) · Roger Lo, MD (1) · Rona Yaegar, MD (1)
PMID 10564685, PMID 15902208, PMID 15958804, PMID 17975015, PMID 18032762, PMID 18032763, PMID 19901123, PMID 32501528, PMID 35385748, PMID 36608320, PMID 36811382, PMID 40578933, PMID 8797771
2014 (1)